Boralex's stock price is now closely aligned with Brookfield's proposed take-private offer of C$37.25, raising questions about future growth potential. Analysts are adjusting their forecasts as the deal approaches, revealing a split in sentiment among investors.
As Boralex (TSX:BLX) inches closer to being taken private by Brookfield, the stock's current price target reflects this shift. Analysts have fine-tuned their valuations, with RBC Capital and Scotiabank aligning their targets with Brookfield's offer, while Raymond James signals caution with a downgrade. This evolving narrative is crucial for Canadian investors to watch.
Investor takeaway: Canadian investors should consider how the impending transaction could limit Boralex's growth potential beyond the buyout price.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Brookfield Asset Management Ltd
BAM.TO
BAM.TO
Brookfield Asset Management Ltd
WealthAwesomeMarket cap
$105.71B
P/E
29.8x
52W high
$84.98
52W low
$57.50
1W change
+0.68%
Beta
1.26
Analyst Price Targets
Based on analyst covering BAM
Wall Street analysts forecast BAM stock price to rise 22.0% over the next 12 months.
Consensus
No RatingAvg. Target
C$80.76
+22.0% Upside
Current Price
C$66.20
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BAM's historical volatility
30-Day Vol
31.1%
Annualized
90-Day Vol
27.5%
Annualized
Trend (90d)
-5.6%
Annualized drift
90d Mean
C$64.89
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$65.76 | C$59.07 โ C$73.20 |
| 60 trading days | C$65.32 | C$56.13 โ C$76.02 |
| 90 trading days | C$64.89 | C$53.89 โ C$78.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Brookfield's Offer Anchors Boralex's Valuation at C$37.25
The fair value estimate for Boralex remains steady at C$36.88, with analysts projecting a revenue growth rate of about 4.98%. This stability in valuation contrasts with the cautious outlook from some analysts, who see limited potential for growth once the deal is finalized.
Bull case
- RBC Capital and Scotiabank have raised their price targets for Boralex, supporting the valuation implied by Brookfield's offer.
- The alignment of multiple firms around the C$37.25 price target suggests a consensus that the offer represents fair value for the stock.
Bear case
- Raymond James downgraded Boralex to Market Perform, indicating limited upside beyond the proposed deal price.
- Some analysts are concerned about execution and growth options, suggesting that future performance may not be promising.
Advertisement
